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Abstract 
Lung cancer metastases to the prostate are uncommon, and are usually found incidentally during 
autopsy. This case report describes a 77-year-old man with a large cell neuroendocrine carcinoma 
(LCNEC) of the lung and metastases from this primary cancer in the prostate. During the fol-
low-up after the chemotherapy performed for pulmonary LCNEC, pelvic computed tomography 
revealed a prostatic tumor and prostatic needle biopsy was performed. Histologically, the tumor 
was identified as LCNEC, forming a tissue architecture closely resembling the previously diagnosed 
lung cancer. The tumor cells were immunohistochemically positive for  thyroid  transcription 
factor-1. These findings led to a diagnosis of prostatic metastasis of pulmonary LCNEC. 
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Introduction 
Although prostatic invasion by bladder or rectal 
cancer  reportedly  occurs,  hematogenous  metastasis 
from distant organs to the prostate is extremely rare 
[1-3]. We herein report a case of prostatic metastasis of 
pulmonary  large  cell  neuroendocrine  carcinoma 
(LCNEC). 
Case Report 
 A 77-year-old man noted a swelling in the right 
neck  and  was  referred  to  our  department.  Chest 
computed  tomography  (CT)  revealed  a  tumor  ex-
tending along the bronchus in the S6 region of the left 
lung,  mediastinal lymphadenopathy, and a  mass in 
the  left  chest  wall  (Figure  1A  and  1B).  The  tumor 
marker  NSE  level  (institutional  cutoff  value,  15.0 
ng/mL)  was  elevated  to  81.0  ng/mL,  and  ProGRP 
(institutional cutoff value, 46.0 pg/mL) to 346 pg/mL 
(Figure 2). LCNEC was diagnosed by bronchoscopic 
brushing  cytology  of  the  S6  tumor.  Histologically, 
right cervical lymph node biopsy revealed solid nests 
of  large  tumor  cells  with  finely  granular  chromatin 
and  small  nucleoli  (Figure  3A  and  3B).  On  im-
munostaining, the tumor  cells were positive for cy-
tokeratin AE1/3, thyroid transcription factor (TTF)-1 
and N-CAM, leading to a diagnosis of metastasis of 
pulmonary LCNEC (Figure 3C, 3D and 3E). The pa-
tient received four courses of carboplatin and etopo-
side  combination  chemotherapy,  achieving  a  com-
plete  response,  with  a  normalization  of  NSE  and 
ProGRP (Figure 2). 
 He  developed  symptoms  of  urinary  retention 
four  months  after  the  completion  of  chemotherapy. 
Chest CT showed swollen mediastinal lymph nodes, 
and pelvic CT revealed a massive tumor in the pros-
tate (Figure 1C).  
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Figure  1.  Radiological  findings.  (A,  B) 
Chest CT revealed a peribronchial tumor 
in the S6 of the left lung and bulky medi-
astinal  lymphadenopathy.  The  arrow 
indicates the lymphadenopathy in the left 
chest wall. (C) During post-chemotherapy 
follow-up, pelvic CT revealed a massive 
tumor  in  the  prostate.  (D)  PET/CT 
demonstrated  marked  FDG  uptake 
(SUVmax=19.0) in the prostatic tumor. 
 
 
 
Figure 2. Time course of serum NSE and ProGRP levels. Serum 
NSE and ProGRP levels decreased in response to the first-line 
chemotherapy, but 4 months after the chemotherapy they rose 
again.  Gray  boxes  under  the  graph  indicate  the  duration  of 
chemotherapy. The abscissa is graduated in months.  
 
 
 
 
 
 
 
 
 
The prostatic tumor was inhomogeneous, with 
irregular  borders  and  compression  of  the  urinary 
bladder and rectum. PET/CT showed FDG uptake in 
the mediastinal lymph node and in the prostatic tu-
mor  (Figure  1D).  The  tumor  markers  NSE  and 
ProGRP  were  re-elevated  to  54.5  ng/mL  and  1,260 
pg/mL,  respectively  (Figure  2),  but  the  PSA  was 
normal. Either prostatic metastasis of lung cancer or 
primary prostate cancer was suspected, and prostatic 
needle biopsy was performed. Histologically, the bi-
opsy specimen showed tumor cell infiltration between 
normal  prostate  tissue  and  an  absence  of  prostatic 
intraepithelial neoplasia in the adjacent glands (Fig-
ure 4A). The tumor grew in solid organoid nests con-
sisting of polygonal tumor cells with abundant, finely 
granular  chromatin  and  small  nucleoli  (Figure  4B). 
Immunostaining of the tumor cells was positive for 
cytokeratin AE1/3, TTF-1 and N-CAM (Figure 4C, 4D 
and 4E). These findings are similar to those of the neck 
lymph node biopsy specimen, leading to a diagnosis 
of prostatic metastasis of pre-existing lung cancer. 
The  chemotherapy  regimen  for  pulmonary 
LCNEC, which included carboplatin with irinotecan 
as  the  second-line  and  amrubicin  as  the  third-line 
therapy, was resumed, resulting in shrinkage of the 
enlarged prostate. The symptoms of urinary retention 
improved and surgical intervention, such as urethral 
stent  placement  and  transurethral  tumor  resection, 
was  not  required.  Although  prostate  metastasis  re-
mained regressed and no metastases were found in 
the brain, bone or liver, the patient developed multi-
ple pulmonary metastases 10 months after the com-
pletion  of  the  third-line  chemotherapy  and  died  of 
respiratory failure. Autopsy was not performed. 
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Figure 3. Histology of a neck lymph 
node biopsy specimen. (A) Histolog-
ically,  solid  nests  with  peripheral 
palisading  were  observed.  (B)  The 
nuclear chromatin ranges from fine to 
vesicular  and  many  cells  have  small 
nucleoli.  (C-E)  On  immunohisto-
chemical  staining,  the  tumor  cells 
were positive for cytokeratin AE1/3, 
TTF-1, and N-CAM, respectively (C, 
cytokeratin  AE1/3;  D,  TTF-1;  E, 
N-CAM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.  Histology  of  a  prostate 
biopsy specimen. (A) The tumor cells 
proliferated  in  solid  nests  between 
the normal prostate tissues. (B) Tu-
mor cells display fine chromatin and 
small  nucleoli.  (C-E)  On  immuno-
histochemical staining, the tumor cells 
were positive for cytokeratin AE1/3, 
TTF-1, and N-CAM, respectively (C, 
cytokeratin  AE1/3;  D,  TTF-1;  E, 
N-CAM).  Journal of Cancer 2012, 3 
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Discussion 
 LCNEC of the lung is a variant of a large cell 
carcinoma  which  exhibits  neuroendocrine  architec-
tural  features  and  immunohistochemical  or  ultra-
structural evidence of neuroendocrine differentiation 
[4, 5]. The majority of previous studies reported that 
LCNEC is associated with poor survival compared to 
stage-matched non-small cell lung cancer, approach-
ing the very poor prognosis of small cell lung cancer 
[6-8].  LCNEC  accounts  for  approximately  3%  of  all 
pulmonary malignancies [9, 10]. 
 The urogenital tract is an unusual site of metas-
tasis. Johnson et al. analyzed 1,474 autopsy cases of 
malignant  prostate  disease,  and  identified  a  meta-
static prostatic lesion in only a total of 18 cases (1.2%) 
[2]. The primary tumor site was a melanoma in 9 cases 
and lung cancer in 5. Secondary prostatic malignan-
cies are mainly due to an invasion by bladder or rectal 
cancer, and are rarely metastatic in origin.  
A search of the literature revealed only one pre-
viously reported case of prostatic metastasis of pul-
monary  LCNEC.  Yoo  et  al.  reported  a  70-year-old 
man with pulmonary LCNEC and metastases in the 
prostate,  brain,  bone,  liver,  and  lymph  nodes  [11]. 
Their patient showed multiple organ metastases at the 
first  examination,  and  he  died  after  only  6  days  of 
chemotherapy.  In  our  case,  fortunately,  the  chemo-
therapy seemed to be comparatively effective in terms 
of a period of event-free survival.  
Reports  of  LCNEC  arising  in  the  prostate,  de-
fined by the criteria for pulmonary LCNEC, are ex-
tremely rare, but in this case, prostatic metastasis of 
the  pulmonary  LCNEC  needed  to  be  differentiated 
from primary prostatic LCNEC [12, 13]. In the pres-
ence of pre-existing primary pulmonary LCNEC, the 
prostate  tumor  appeared  to  progress  in  accordance 
with the tumor marker levels. There was no increase 
in serum PSA, which is specific to primary prostate 
cancer. The prostate biopsy specimen was composed 
of  normal  prostate  tissue  mixed  with  tumor  tissue 
resembling  that  of  the  previously  diagnosed  lung 
cancer.  In  addition,  the  tumor  cells  were  immuno-
histochemically positive for TTF-1. These findings led 
to  a  diagnosis  of  hematogenous  metastasis  of  pul-
monary LCNEC to the prostate. This case suggests the 
need to actively perform a prostate biopsy for an ac-
curate diagnosis. In addition, TTF-1 immunostaining, 
normally  positive  in  lung  cancer,  is  suggested  as  a 
means  of  differentiating  primary  lung  cancer  from 
primary prostate cancer [14]. 
 The lack of androgen and estrogen receptors in 
primary LCNEC of the prostate and lung is the bio-
logical basis for the failure of antiandrogen therapy in 
patients  with  LCNEC.  Consequently,  chemotherapy 
using pulmonary LCNEC regimens is the therapy of 
choice  for  patients  with  a  prostatic  metastasis  of 
pulmonary LCNEC. Although the optimum chemo-
therapy  for  pulmonary  LCNEC  remains  undefined, 
chemotherapy  for  small-cell  lung  cancer  afforded 
disease control in this case. 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
[1]  Bates  AW,  Baithun  SI.  Secondary  solid  neoplasms  of  the 
prostate:  a  clinico-pathological  series  of  51  cases.  Virchows 
Arch. 2002; 440: 392-396. 
[2]  Johnson DE, Chalbaud R, Ayala AG. Secondary tumors of the 
prostate. J Urol. 1974; 112: 507-508. 
[3]  Zein TA, Huben  R,  Lane  W,  et al.  Secondary  tumors  of  the 
prostate. J Urol. 1985; 133: 615-616. 
[4]  Travis  WD,  Linnoila  RI,  Tsokos  MG,  et  al.  Neuroendocrine 
tumors  of  the  lung  with  proposed  criteria  for  large-cell 
neuroendocrine  carcinoma.  An  ultrastructural, 
immunohistochemical, and flow cytometric study of 35 cases. 
Am J Surg Pathol. 1991; 15: 529-553. 
[5]  Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 
pulmonary neuroendocrine tumors with clarification of criteria 
for atypical carcinoid and its separation from typical carcinoid. 
Am J Surg Pathol. 1998; 22: 934-944. 
[6]  Jiang SX, Kameya T, Shoji M, et al. Large cell neuroendocrine 
carcinoma of the lung: a histologic and immunohistochemical 
study of 22 cases. Am J Surg Pathol. 1998; 22: 526-537. 
[7]  Veronesi  G,  Morandi  U,  Alloisio  M,  et  al.  Large  cell 
neuroendocrine carcinoma of the lung: a retrospective analysis 
of 144 surgical cases. Lung Cancer. 2006; 53: 111-115. 
[8]  Warren WH, Faber LP, Gould VE. Neuroendocrine neoplasms 
of the lung. A clinicopathologic update. J Thorac Cardiovasc 
Surg. 1989; 98: 321-332. 
[9]  Fernandez  FG,  Battafarano  RJ.  Large-cell  neuroendocrine 
carcinoma of the lung. Cancer Control. 2006; 13: 270-275. 
[10] Paci M, Cavazza A, Annessi V, et al. Large cell neuroendocrine 
carcinoma of the lung: a 10-year clinicopathologic retrospective 
study. Ann Thorac Surg. 2004; 77: 1163-1167. 
[11] Yoo JH, Lee JH, Kim EK, et al. Prostatic metastasis of large cell 
neuroendocrine carcinoma of the lung. Respirology. 2009; 14: 
772-775. 
[12] Evans  AJ,  Humphrey  PA,  Belani  J,  et  al.  Large  cell 
neuroendocrine  carcinoma  of  prostate:  a  clinicopathologic 
summary  of  7  cases  of  a  rare  manifestation  of  advanced 
prostate cancer. Am J Surg Pathol. 2006; 30: 684-693. 
[13] Fernandes  RC,  Matsushita  MM,  Mauad  T,  et  al.  Prostate 
carcinoma with neuroendocrine differentiation: case report and 
literature review. Rev Hosp Clin Fac Med Sao Paulo. 2001; 56: 
153-158. 
[14] Ordonez  NG.  Value  of  thyroid  transcription  factor-1 
immunostaining in distinguishing small cell lung carcinomas 
from other small cell carcinomas. Am J Surg Pathol. 2000; 24: 
1217-1223. 